{"url_path":"/sec/cprx/8-k/2026-07-16/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-16","source_url":"https://www.sec.gov/Archives/edgar/data/1369568/0001193125-26-304984-index.html","accession_number":"0001193125-26-304984","cik":"0001369568","ticker":"CPRX","issuer_name":"CATALYST PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1369568/0001193125-26-304984-index.html","primary_entity_key":"0001369568","primary_entity_name":"CATALYST PHARMACEUTICALS, INC."},"word_count":201,"has_tables":true,"body_markdown":"Item 9.01. Financial Statements and Exhibits.\n\n \n\n(d)\n\nExhibits.\n\n \n\nExhibit\n\nNumber\n\n  \n\nDescription\n\n2.1\n\n  \n\n[Agreement and Plan of Merger, dated as of May 6, 2026, by and among Catalyst Pharmaceuticals, Inc., Angelini Pharma S.p.A. and Angelini Cielo Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the SEC on May 7, 2026).*](http://www.sec.gov/Archives/edgar/data/1369568/000119312526210518/d90722dex21.htm)\n\n3.1\n\n  \n\n[Amended and Restated Certificate of Incorporation of Catalyst Pharmaceuticals, Inc.](d159184dex31.htm)\n\n3.2\n\n  \n\n[Amended and Restated By-laws of Catalyst Pharmaceuticals, Inc.](d159184dex32.htm)\n\n104\n\n  \n\nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n*\n\nSchedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC; provided, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedules so furnished.\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nCatalyst Pharmaceuticals, Inc.\n\nDated: July 15, 2026\n\n \n\n \n\nBy:\n\n \n\n/s/ Michael W. Kalb\n\n \n\n \n\n \n\nName: Michael W. Kalb\n\n \n\n \n\n \n\nTitle:  Executive Vice President and Chief Financial Officer"}